Bayer and Roche plan OTC merger in US
Tuesday 17 September 1996
The merger, unveiled yesterday, involves the formation of a 50-50 joint venture to market non-prescription analgesics and women's health formulations. The combined entity is expected to have sales of $275m in its early years, although Bayer's asprin will not be sold by the new entity.
It is just two years since Bayer paid SmithKline Beecham $1bn to buy back the right to use its brand name in North America, seized by the US government during the First World War. Bayer will handle sales and marketing in the venture, which the German group claimed would now be a contender for third place amongst over-the-counter groups in US "and will compete even more significantly in the US OTC analgesic market''.
That market is estimated to be worth around $12.5bn or a quarter of the world's total. Growth is being propelled by the trend to "self-medication" and the desire by insurance companies and governments to cut health costs.
The venture will include Roche's Aleve analgesic and Femstat 3 for vaginal yeast infections, which Bayer said would add at least $200m to sales of its US consumer care division worth $600m in 1995. Bayer products to be sold by the new venture will include Actron and Vanquish analgesics, Midol menstrual pain reliever and Mycelex-7 vaginal yeast infection treatment. Other big Bayer brands such as Alka-Seltzer, Alka-Seltzer Plus, One-A- Day and Flintstones vitamins will be excluded from the deal.
- 1 Saudi preacher who 'raped and tortured' his five -year-old daughter to death is released after paying 'blood money'
- 2 Russian girl takes her own life after parents find pornography on her computer
- 3 Kim Kardashian on Bruce Jenner's 'story': 'We support him no matter what, and I think when the time is right, he'll talk'
- 4 Ball pool for adults opens in London
- 5 Amal Clooney gives excellent response to fashion question at European Court of Human Rights
Russian girl takes her own life after parents find pornography on her computer
Kim Kardashian on Bruce Jenner's 'story': 'We support him no matter what, and I think when the time is right, he'll talk'
Michelle Obama highlights harsh restrictions faced by Saudi women after meeting King Salman without wearing a headscarf
Ball pool for adults opens in London
Amal Clooney gives excellent response to fashion question at European Court of Human Rights
9 reasons Greece's experiment with the radical left is doomed to failure
'We would evict Queen from Buckingham Palace and allocate her council house,' say Greens
Greece elections: Syriza and EU on collision course after election win for left-wing party
Have we reached 'peak food'? Shortages loom as global production rates slow
British Muslim school children suffering a backlash of abuse following Paris attacks
British grandmother Lindsay Sandiford faces execution by firing squad in Indonesia
iJobs Money & Business
£13000 per annum: Recruitment Genius: This Pension Specialist was established ...
£23000 - £26000 per annum + Benefits: Ashdown Group: Market Research Executive...
£25000 - £35000 per annum: Recruitment Genius: A Technical Report Writer is re...
Competitive salary & benefits!: MBDA UK Ltd: MBDA UK LTD Indirect Procurement...